all report title image
  • Published In : May 2024
  • Code : CMI1728
  • Pages :205
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Market Size and Trends

Global cell therapy manufacturing market is estimated to be valued at USD 4.91 Bn in 2024 and is expected to reach USD 12.96 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.9% from 2024 to 2031.

Cell Therapy Manufacturing Market Key Factors

To learn more about this report, request a free sample copy

Increasing prevalence of chronic diseases such as cancer and cardiovascular diseases boosts demand for cell therapy products across the world. The advancements in cell therapy research and development and rise in the number of clinical trials are driving the market growth. Various market players are constantly focused on developing innovative cell therapy products, in order to expand their market share. Regulatory complexity and high costs involved can hamper the growth of the cell therapy manufacturing market.

Increasing Launch of Various Types of Technologies for Cell Therapy Manufacturing

Manufacturers are involved in developing and launching various types of technologies for cell therapy manufacturing, and this is expected to drive the growth of global cell therapy manufacturing market. For instance, in July 2022, INVETECH, a global company offering solutions, systems, and services to cell and gene therapy, announced the launch of new korus technology for autologous cell therapy production. Korus is a closed system for the production of autologous cell therapy.

Increasing Regulatory Approvals by Regulatory Authorities

Manufacturers of cell therapy product are focusing on receiving regulatory approvals to enhance their cell therapy manufacturing process, and this is expected to drive the global cell therapy manufacturing market growth. For instance, in May 2022, Bristol Myers Squibb Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.